Radiation Therapy for Primary Eyelid Cancers in Tunisia.
Identifieur interne : 000473 ( Ncbi/Merge ); précédent : 000472; suivant : 000474Radiation Therapy for Primary Eyelid Cancers in Tunisia.
Auteurs : A. Belaid [France] ; C. Nasr ; M. Benna ; A. Cherif ; O. Jmour ; H. Bouguila ; F. BennaSource :
- Asian Pacific journal of cancer prevention : APJCP [ 1513-7368 ] ; 2016.
Abstract
Management of eyelid cancers is based on surgery and/or radiotherapy (RT). The treatment objective is to control tumors with acceptable functional and esthetic outcomes. The aim of this study was to evaluate the results of radiation therapy in management of epithelial eyelid cancers, reviewing retrospectively the clinical records of patients treated in our institution from January 1989 to December 2013. We focused on clinical and histological features, treatment characteristics, tolerance and disease control. One hundred and eight patients (62 men and 46 women) were enrolled, with a mean age of 61 years [ranges 1587]. The most frequent tumor location was the inner canthus (42.6%). Median tumor size was 21 mm [ranges 470]. Histological type was basal cell carcinoma in 88 cases (81.5%), squamous cell carcinoma in 16 (14.8%) and sebaceous carcinoma in 4 (3.7%). Radiation therapy was exclusive in 67 cases (62%) and postoperative for positive or close margins in the remaining cases. Kilovoltage external beam radiotherapy (KVRT) was used in 63 patients (58.3%) and lowdoserate interstitial brachytherapy in 37 (34.3%). Eight (7.4%) were treated with cobalt or with a combination of KVRTcobalt, KVRTelectron beams, KVRTbrachytherapy or cobaltelectron beams. The total delivered radiation doses were 70 Gy (2 Gy/fraction) in 62 patients (57.4%), 66 Gy (2 Gy/fraction) in 37 (34.3%) and 61.2 Gy (3.4Gy/fraction) in 9 (8.3%). After a median followup of 64 months, we noted 10 cases of local recurrences(9.2%): 7 after exclusive and 3 after postoperative RT. No local recurrence occurred in patients treated with brachytherapy. Actuarial 5year local recurrencefree rate, diseasefree survival and overall survival were respectively 90%, 90% and 97%. Tstage was found to be a significant factor for recurrence (p=0.047). All acute radiationrelated reactions were scored grade I or II. Delayed effects were eye watering in 24 cases (22.2%), eye dryness in 19 (17.6%), unilateral cataract in 7 (6.4%) and ectropion in 4 (3.7%). Radiation therapy and especially brachytherapy is an efficient treatment of eyelid cancers, allowing eye conservation and functional preservation with good local control rates and acceptable toxicity.
PubMed: 27510024
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000007
- to stream PubMed, to step Curation: 000007
- to stream PubMed, to step Checkpoint: 000007
Links to Exploration step
pubmed:27510024Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Radiation Therapy for Primary Eyelid Cancers in Tunisia.</title>
<author><name sortKey="Belaid, A" sort="Belaid, A" uniqKey="Belaid A" first="A" last="Belaid">A. Belaid</name>
<affiliation wicri:level="3"><nlm:affiliation>Radiation oncology department, Salah Azaiez Institute, Tunis, Tunisia Email : asma.belaid@yahoo.fr.</nlm:affiliation>
<country wicri:rule="url">France</country>
<wicri:regionArea>Radiation oncology department, Salah Azaiez Institute, Tunis</wicri:regionArea>
<placeName><settlement type="city">Tunis</settlement>
<region nuts="2">Gouvernorat de Tunis</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nasr, C" sort="Nasr, C" uniqKey="Nasr C" first="C" last="Nasr">C. Nasr</name>
</author>
<author><name sortKey="Benna, M" sort="Benna, M" uniqKey="Benna M" first="M" last="Benna">M. Benna</name>
</author>
<author><name sortKey="Cherif, A" sort="Cherif, A" uniqKey="Cherif A" first="A" last="Cherif">A. Cherif</name>
</author>
<author><name sortKey="Jmour, O" sort="Jmour, O" uniqKey="Jmour O" first="O" last="Jmour">O. Jmour</name>
</author>
<author><name sortKey="Bouguila, H" sort="Bouguila, H" uniqKey="Bouguila H" first="H" last="Bouguila">H. Bouguila</name>
</author>
<author><name sortKey="Benna, F" sort="Benna, F" uniqKey="Benna F" first="F" last="Benna">F. Benna</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27510024</idno>
<idno type="pmid">27510024</idno>
<idno type="wicri:Area/PubMed/Corpus">000007</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000007</idno>
<idno type="wicri:Area/PubMed/Curation">000007</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000007</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000007</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000007</idno>
<idno type="wicri:Area/Ncbi/Merge">000473</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Radiation Therapy for Primary Eyelid Cancers in Tunisia.</title>
<author><name sortKey="Belaid, A" sort="Belaid, A" uniqKey="Belaid A" first="A" last="Belaid">A. Belaid</name>
<affiliation wicri:level="3"><nlm:affiliation>Radiation oncology department, Salah Azaiez Institute, Tunis, Tunisia Email : asma.belaid@yahoo.fr.</nlm:affiliation>
<country wicri:rule="url">France</country>
<wicri:regionArea>Radiation oncology department, Salah Azaiez Institute, Tunis</wicri:regionArea>
<placeName><settlement type="city">Tunis</settlement>
<region nuts="2">Gouvernorat de Tunis</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nasr, C" sort="Nasr, C" uniqKey="Nasr C" first="C" last="Nasr">C. Nasr</name>
</author>
<author><name sortKey="Benna, M" sort="Benna, M" uniqKey="Benna M" first="M" last="Benna">M. Benna</name>
</author>
<author><name sortKey="Cherif, A" sort="Cherif, A" uniqKey="Cherif A" first="A" last="Cherif">A. Cherif</name>
</author>
<author><name sortKey="Jmour, O" sort="Jmour, O" uniqKey="Jmour O" first="O" last="Jmour">O. Jmour</name>
</author>
<author><name sortKey="Bouguila, H" sort="Bouguila, H" uniqKey="Bouguila H" first="H" last="Bouguila">H. Bouguila</name>
</author>
<author><name sortKey="Benna, F" sort="Benna, F" uniqKey="Benna F" first="F" last="Benna">F. Benna</name>
</author>
</analytic>
<series><title level="j">Asian Pacific journal of cancer prevention : APJCP</title>
<idno type="ISSN">1513-7368</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Management of eyelid cancers is based on surgery and/or radiotherapy (RT). The treatment objective is to control tumors with acceptable functional and esthetic outcomes. The aim of this study was to evaluate the results of radiation therapy in management of epithelial eyelid cancers, reviewing retrospectively the clinical records of patients treated in our institution from January 1989 to December 2013. We focused on clinical and histological features, treatment characteristics, tolerance and disease control. One hundred and eight patients (62 men and 46 women) were enrolled, with a mean age of 61 years [ranges 1587]. The most frequent tumor location was the inner canthus (42.6%). Median tumor size was 21 mm [ranges 470]. Histological type was basal cell carcinoma in 88 cases (81.5%), squamous cell carcinoma in 16 (14.8%) and sebaceous carcinoma in 4 (3.7%). Radiation therapy was exclusive in 67 cases (62%) and postoperative for positive or close margins in the remaining cases. Kilovoltage external beam radiotherapy (KVRT) was used in 63 patients (58.3%) and lowdoserate interstitial brachytherapy in 37 (34.3%). Eight (7.4%) were treated with cobalt or with a combination of KVRTcobalt, KVRTelectron beams, KVRTbrachytherapy or cobaltelectron beams. The total delivered radiation doses were 70 Gy (2 Gy/fraction) in 62 patients (57.4%), 66 Gy (2 Gy/fraction) in 37 (34.3%) and 61.2 Gy (3.4Gy/fraction) in 9 (8.3%). After a median followup of 64 months, we noted 10 cases of local recurrences(9.2%): 7 after exclusive and 3 after postoperative RT. No local recurrence occurred in patients treated with brachytherapy. Actuarial 5year local recurrencefree rate, diseasefree survival and overall survival were respectively 90%, 90% and 97%. Tstage was found to be a significant factor for recurrence (p=0.047). All acute radiationrelated reactions were scored grade I or II. Delayed effects were eye watering in 24 cases (22.2%), eye dryness in 19 (17.6%), unilateral cataract in 7 (6.4%) and ectropion in 4 (3.7%). Radiation therapy and especially brachytherapy is an efficient treatment of eyelid cancers, allowing eye conservation and functional preservation with good local control rates and acceptable toxicity.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">27510024</PMID>
<DateCreated><Year>2016</Year>
<Month>8</Month>
<Day>11</Day>
</DateCreated>
<DateRevised><Year>2016</Year>
<Month>8</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1513-7368</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>17</Volume>
<Issue>7</Issue>
<PubDate><Year>2016</Year>
</PubDate>
</JournalIssue>
<Title>Asian Pacific journal of cancer prevention : APJCP</Title>
<ISOAbbreviation>Asian Pac. J. Cancer Prev.</ISOAbbreviation>
</Journal>
<ArticleTitle>Radiation Therapy for Primary Eyelid Cancers in Tunisia.</ArticleTitle>
<Pagination><MedlinePgn>3643-6</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Management of eyelid cancers is based on surgery and/or radiotherapy (RT). The treatment objective is to control tumors with acceptable functional and esthetic outcomes. The aim of this study was to evaluate the results of radiation therapy in management of epithelial eyelid cancers, reviewing retrospectively the clinical records of patients treated in our institution from January 1989 to December 2013. We focused on clinical and histological features, treatment characteristics, tolerance and disease control. One hundred and eight patients (62 men and 46 women) were enrolled, with a mean age of 61 years [ranges 1587]. The most frequent tumor location was the inner canthus (42.6%). Median tumor size was 21 mm [ranges 470]. Histological type was basal cell carcinoma in 88 cases (81.5%), squamous cell carcinoma in 16 (14.8%) and sebaceous carcinoma in 4 (3.7%). Radiation therapy was exclusive in 67 cases (62%) and postoperative for positive or close margins in the remaining cases. Kilovoltage external beam radiotherapy (KVRT) was used in 63 patients (58.3%) and lowdoserate interstitial brachytherapy in 37 (34.3%). Eight (7.4%) were treated with cobalt or with a combination of KVRTcobalt, KVRTelectron beams, KVRTbrachytherapy or cobaltelectron beams. The total delivered radiation doses were 70 Gy (2 Gy/fraction) in 62 patients (57.4%), 66 Gy (2 Gy/fraction) in 37 (34.3%) and 61.2 Gy (3.4Gy/fraction) in 9 (8.3%). After a median followup of 64 months, we noted 10 cases of local recurrences(9.2%): 7 after exclusive and 3 after postoperative RT. No local recurrence occurred in patients treated with brachytherapy. Actuarial 5year local recurrencefree rate, diseasefree survival and overall survival were respectively 90%, 90% and 97%. Tstage was found to be a significant factor for recurrence (p=0.047). All acute radiationrelated reactions were scored grade I or II. Delayed effects were eye watering in 24 cases (22.2%), eye dryness in 19 (17.6%), unilateral cataract in 7 (6.4%) and ectropion in 4 (3.7%). Radiation therapy and especially brachytherapy is an efficient treatment of eyelid cancers, allowing eye conservation and functional preservation with good local control rates and acceptable toxicity.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Belaid</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Radiation oncology department, Salah Azaiez Institute, Tunis, Tunisia Email : asma.belaid@yahoo.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nasr</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Benna</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cherif</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jmour</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bouguila</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Benna</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
</AuthorList>
<Language>ENG</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Thailand</Country>
<MedlineTA>Asian Pac J Cancer Prev</MedlineTA>
<NlmUniqueID>101130625</NlmUniqueID>
<ISSNLinking>1513-7368</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>8</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>8</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>8</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27510024</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Gouvernorat de Tunis</li>
</region>
<settlement><li>Tunis</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Benna, F" sort="Benna, F" uniqKey="Benna F" first="F" last="Benna">F. Benna</name>
<name sortKey="Benna, M" sort="Benna, M" uniqKey="Benna M" first="M" last="Benna">M. Benna</name>
<name sortKey="Bouguila, H" sort="Bouguila, H" uniqKey="Bouguila H" first="H" last="Bouguila">H. Bouguila</name>
<name sortKey="Cherif, A" sort="Cherif, A" uniqKey="Cherif A" first="A" last="Cherif">A. Cherif</name>
<name sortKey="Jmour, O" sort="Jmour, O" uniqKey="Jmour O" first="O" last="Jmour">O. Jmour</name>
<name sortKey="Nasr, C" sort="Nasr, C" uniqKey="Nasr C" first="C" last="Nasr">C. Nasr</name>
</noCountry>
<country name="France"><region name="Gouvernorat de Tunis"><name sortKey="Belaid, A" sort="Belaid, A" uniqKey="Belaid A" first="A" last="Belaid">A. Belaid</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/CobaltMaghrebV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000473 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000473 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Terre |area= CobaltMaghrebV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:27510024 |texte= Radiation Therapy for Primary Eyelid Cancers in Tunisia. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27510024" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a CobaltMaghrebV1
This area was generated with Dilib version V0.6.32. |